A Double-blind, Randomized, Placebo Controlled, Combined Single and Multiple Ascending Dose, Phase 1 Study to Investigate the Safety, Tolerability and Pharmacokinetic and Pharmacodynamics of PG-102(MG12) in Healthy Volunteers
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, combined single (Part A) multiple (Part B) ascending dose, phase 1 study to investigate the safety, tolerability and pharmacokinetic and pharmacodynamics following subcutaneous injections of PG-102(MG12) in healthy adult participants.
This study will be conducted in 2 Parts (Part A and B), with up to 5 cohorts in each part (Part A; Cohorts A1 to A5 and Part B; Cohorts B1 to B5).
100 项与 ProGen Co., Ltd. 相关的临床结果
0 项与 ProGen Co., Ltd. 相关的专利(医药)
100 项与 ProGen Co., Ltd. 相关的药物交易
100 项与 ProGen Co., Ltd. 相关的转化医学